Premium
Association of tumour necrosis factor ‐ α gene (T‐1031C, C‐863A, and C‐857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette‐Guérin immunotherapy
Author(s) -
Ahirwar Dinesh K.,
Mandhani Anil,
Dharaskar Anand,
Kesarwani Pravin,
Mittal Rama D.
Publication year - 2009
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2009.08549.x
Subject(s) - bladder cancer , odds ratio , genotype , medicine , immunotherapy , genotyping , haplotype , oncology , cancer , immunology , hazard ratio , bcg vaccine , gastroenterology , confidence interval , gene , biology , vaccination , genetics
OBJECTIVE To investigate the association of tumour necrosis factor‐α gene ( TNF‐α ) polymorphisms T‐1031C, C‐863A, and C‐857T with bladder cancer risk and recurrence after bacille Calmette‐Guérin (BCG) immunotherapy, as TNF‐α regulates inflammatory process influencing bladder cancer susceptibility and outcome of BCG immunotherapy. PATIENTS AND METHODS In all, 220 patients with bladder cancer and 206 controls were recruited. Genotyping was done using allele specific‐polymerase chain reaction. RESULTS A T‐1031C, CC genotype and haplotype −1031C/−863C/−857T showed enhanced susceptibility to bladder cancer, with an odds ratio (OR) of 2.23 and 95% confidence interval (CI) of 1.17–4.26; and an OR of 6.05 and 95%CI of 2.46–14.90, respectively. A T‐1031C, CC genotype had a reduced risk of recurrence after BCG treatment (hazard ratio 0.38, 95%CI 0.14–0.98). CONCLUSION The present data suggests that T‐1031C (CC) genotype and C/C/T haplotype may confer risk for bladder cancer, moreover T‐1031C (CC) decreased the risk of recurrence after BCG immunotherapy.